IGRT

Siteman Cancer Center Begins Treatment with Latest Mevion Proton Therapy System

Retrieved on: 
Thursday, November 16, 2023
Research, Hospitals, Health Technology, Radiology, Health, University, Science, Education, Oncology, Proton, Lung, Neck, NCI-designated Cancer Center, Brain, Radiation, Proton therapy, Head, Barnes-Jewish Hospital, Risk, FLASH, Intensity, Hospital, Scan (company), Varian Medical Systems, Breast cancer, NCI, Patient, Multimedia, Heart, IGRT, Image-guided radiation therapy, Metal toxicity, MLC, 3D, Professor, Medical imaging, Pharmaceutical industry

Mevion Medical Systems announced today that the world’s first single-room proton therapy system has completed the upgrade to the latest MEVION S250i Proton Therapy System® with FLASH* capabilities, and has begun treating patients in November at the S. Lee Kling Proton Therapy Center at Siteman Cancer Center, Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis, MO.

Key Points: 
  • Mevion Medical Systems announced today that the world’s first single-room proton therapy system has completed the upgrade to the latest MEVION S250i Proton Therapy System® with FLASH* capabilities, and has begun treating patients in November at the S. Lee Kling Proton Therapy Center at Siteman Cancer Center, Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis, MO.
  • View the full release here: https://www.businesswire.com/news/home/20231116635095/en/
    The MEVION S250i Proton Therapy System (Photo: Business Wire)
    Siteman Cancer Center is an NCI-designated Comprehensive Cancer Center that draws patients from Missouri, Southern Illinois and beyond.
  • “Our team also looks forward to advancing FLASH dosimetry research.”
    This latest system incorporates Mevion's cutting-edge HYPERSCAN® Pencil Beam Scanning for Intensity Modulated Proton Therapy (IMPT) with a proton MLC, along with an advanced 3D imaging system for high-precision Image-Guided Radiation Therapy (IGRT) and adaptive therapy.
  • These latest capabilities are the result of a collaborative effort between Mevion and Siteman Cancer Center, initiated in 2019.

Mevion Selected to Equip BayCare’s Proton Therapy Center in Tampa

Retrieved on: 
Friday, November 3, 2023
Medical Devices, Hospitals, Health, Radiology, Oncology, Proton, Science, IGRT, Center of excellence, Laboratory, Central Florida, Heart, Varian Medical Systems, FLASH, Winter Haven Hospital, Cancer Institute, DECT, FIT, Franciscan Sisters of Allegany, Internal medicine, Hospital, Proton therapy, MLC, CT, Stroke, Neurosurgery, Fred J. Ansfield, Franciscan Sisters, Cancer, ARC, BayCare Ballpark, Patient, Intensity, Scan (company), Morton Plant Hospital, Medical imaging, Nursing, Tampa Bay

Mevion Medical Systems, the leading provider of compact single-room proton therapy systems, is pleased to announce it has been selected by BayCare to equip the St. Joseph’s Hospital Cancer Institute in Tampa with a MEVION S250-FIT Proton Therapy System™*.

Key Points: 
  • Mevion Medical Systems, the leading provider of compact single-room proton therapy systems, is pleased to announce it has been selected by BayCare to equip the St. Joseph’s Hospital Cancer Institute in Tampa with a MEVION S250-FIT Proton Therapy System™*.
  • “BayCare is bringing an advanced proton radiation therapy center to Tampa so patients in our community don’t have to drive to Orlando or beyond to get this level of high-quality care.”
    The MEVION S250-FIT Proton Therapy System is thoughtfully designed to expedite proton therapy project timelines with a compact footprint, reduced construction requirements, and accelerated installation process.
  • “We are dedicated to advancing proton therapy technology and access, and I look forward to making a meaningful difference to patients and families across West Central Florida.”
    *The MEVION S250-FIT Proton Therapy System, FLASH therapy, online adaptive therapy, and ARC therapy are not yet available for clinical use.
  • Dedicated to advancing the design and accessibility of proton therapy worldwide, Mevion pioneered the single-room platform and continues to further the science and application of proton therapy.

"Study Radiation Therapy With Erin" Podcast Fuels Global Interest as "2022-2023 Radiation Therapy Market Summary Report" is Released

Retrieved on: 
Wednesday, October 11, 2023
Diagnosis, Acquisition, Breast cancer, IMV, RT, Data analysis, Brachytherapy, Radiation, Keiser University, IGRT, Cancer, EBRT, OEM, Woman, Patient, Medical imaging

The 2022-2023 Radiation Therapy Market Summary Report is a meticulous compilation of data, presenting a panoramic view of key radiation therapy technologies, ranging from external beam radiation therapy (EBRT) and image-guided radiotherapy (IGRT) to brachytherapy equipment and sophisticated simulators.

Key Points: 
  • The 2022-2023 Radiation Therapy Market Summary Report is a meticulous compilation of data, presenting a panoramic view of key radiation therapy technologies, ranging from external beam radiation therapy (EBRT) and image-guided radiotherapy (IGRT) to brachytherapy equipment and sophisticated simulators.
  • Holistic View of Radiation Therapy: The report comprehensively covers the range of radiation therapy technologies used in treating cancer patients, highlighting trends in patient volume, installed equipment, market share, and more.
  • For businesses, entrepreneurs, and managers in the healthcare sector, the 2022-2023 Radiation Therapy Market Summary Report is more than just data; it's the roadmap to understanding and navigating the rapidly evolving world of radiation therapy.
  • To invest in your business's future and to gain a robust understanding of the radiation therapy market, make sure to acquire the 2022-2023 Radiation Therapy Market Summary Report.

Global Radiation Therapy Market Forecast Report 2023-2027: A $13.28 Billion Market in 2027 - ResearchAndMarkets.com

Retrieved on: 
Monday, June 26, 2023
Health, Pharmaceutical, Proton, Urbanization, Hitachi, Ion Beam Applications, Hospital, COVID-19, Ageing, Radiation, IGRT, Radiosurgery, Particle accelerator, Incidence, US, Proton therapy, Growth, IMRT, Medical imaging, Tomotherapy, LINAC

The "Global Radiation Therapy Market with Focus on LINAC: Insights & Forecast (2023-2027)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Radiation Therapy Market with Focus on LINAC: Insights & Forecast (2023-2027)" report has been added to ResearchAndMarkets.com's offering.
  • The global radiation therapy market is expected to reach US$13.28 billion in 2027, witnessing growth at a CAGR of 6.77%, over the period 2023-2027.
  • The global radiation therapy market can be categorized into external beam radiation therapy, internal beam radiation therapy and others (systemic radiotherapy) on the basis of type.
  • Depending upon the type, the global external beam radiation therapy market can be categorized into following categories: Intensity-Modulated Radiation Therapy (IMRT), Image-Guided Radiation Therapy (IGRT), Tomotherapy, Stereotactic Radiosurgery, Stereotactic Body Radiation Therapy and Proton Therapy.

American Shared Hospital Services Reports 18% Period-over-Period Increase in Third Quarter 2022 Revenue to $4.8 Million

Retrieved on: 
Thursday, November 10, 2022
SAN, GLOBE, Review, Income, Trigeminal neuralgia, Marketing, NYSE, Leadership, PBRT, Proton therapy, U.S. Securities and Exchange Commission, HVS Global Hospitality Services, Orlando Health, Century, Annual general meeting, Radiosurgery, Leeds Gamma Knife Centre, Risk, Depreciation, Webcast, Loss, Malignancy, Annual report, CA, EBITDA, AMS, Contract, Pectus carinatum, Company, Home After Three Months Away, Nine Months, ASHS, GAAP, IGRT, Growth, Security (finance), VP, IMRT, CMS, COVID-19, Lithium, Video game, Health insurance, Pharmaceutical industry, Medical imaging, Bookkeeping, Bank

SAN FRANCISCO, CA, Nov. 10, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- American Shared Hospital Services (NYSE American: AMS) (the "Company"), a leading provider of turnkey technology solutions for stereotactic radiosurgery and advanced radiation therapy equipment and services, today announced financial results for the third quarter and nine months of fiscal 2022, ended September 30, 2022.

Key Points: 
  • The gross margin percentage expanded 470 basis points to 40.5% of revenue compared to 35.8% for the third quarter of 2021.
  • Operating income for the third quarter of 2022 was $448,000 compared to operating income of $186,000 in the third quarter of 2021, an increase of 140.9%.
  • Adjusted EBITDA, a non-GAAP financial measure, was $1,999,000 for the third quarter of 2022, compared to $1,562,000 for the third quarter of 2021, an increase of 28.0%.
  • Cash at September 30, 2022 was $11,664,000, an increase of $3,401,000 from the December 31, 2021 balance of $8,263,000.

American Shared Hospital Services Announces Third Quarter 2022 Earnings Conference Call

Retrieved on: 
Thursday, November 3, 2022
Proton therapy, Company, CA, Pectus carinatum, Call, GLOBE, Trigeminal neuralgia, NYSE, IGRT, Pain scale, IMRT, AMS, Radiosurgery, Malignancy, Medical imaging, Conference

SAN FRANCISCO, CA, Nov. 03, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – American Shared Hospital Services (NYSE American: AMS) (the "Company"), a leading provider of turnkey technology solutions for stereotactic radiosurgery and advanced radiation therapy equipment and services, today announced that the Company will hold a quarterly conference call to discuss its third quarter 2022 financial results on Thursday November 10th, 2022 at 3:00 pm ET / 12:00 pm PT. The third quarter 2022 financial results press release will be issued before the market open on Thursday, November 10, 2022.

Key Points: 
  • Conference Call on Thursday November 10th, 2022 at 3:00 pm ET / 12:00 pm PT
    SAN FRANCISCO, CA, Nov. 03, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire American Shared Hospital Services (NYSE American: AMS) (the "Company"), a leading provider of turnkey technology solutions for stereotactic radiosurgery and advanced radiation therapy equipment and services, today announced that the Company will hold a quarterly conference call to discuss its third quarter 2022 financial results on Thursday November 10th, 2022 at 3:00 pm ET / 12:00 pm PT.
  • The third quarter 2022 financial results press release will be issued before the market open on Thursday, November 10, 2022.
  • To participate, please call 1 (844) 413-3972 at least 10 minutes prior to the start of the call and ask to join the American Shared Hospital Services call.
  • About American Shared Hospital Services (NYSE American: AMS)
    American Shared Hospital Services is a leading provider of turnkey technology solutions for stereotactic radiosurgery and advanced radiation therapy equipment and services.

Mevion Introduces New MEVION S250-FIT Proton Therapy System

Retrieved on: 
Friday, October 21, 2022
Research, Medical Devices, Other Health, Biotechnology, Radiology, General Health, Pharmaceutical, Health, Science, Oncology, Proton, LinkedIn, Transform, Hospital, Science, FLASH, Integration, LINAC, Patient, Research, Entrepreneurship, Annual general meeting, Multimedia, Harvard Medical School, Partnership, Varian Medical Systems, Cancer, Technology, C. C. Wang, Proton therapy, MD, Scan (company), Massachusetts General Hospital, Doctor of Philosophy, Industry, CEO, IGRT, Central Waqf Council, FIT, ARC, Radiation, Exhibition, Intensity, Mass, Medical imaging

Mevion Medical Systems, the leading provider of compact proton therapy systems for use in radiation treatment for cancer patients, today introduced its new product, the MEVION S250-FIT Proton Therapy System.

Key Points: 
  • Mevion Medical Systems, the leading provider of compact proton therapy systems for use in radiation treatment for cancer patients, today introduced its new product, the MEVION S250-FIT Proton Therapy System.
  • View the full release here: https://www.businesswire.com/news/home/20221021005026/en/
    The MEVION S250-FIT Proton Therapy System (Photo: Business Wire)
    Enabled by the worlds smallest self-shielded proton accelerator from Mevion, the MEVION S250-FIT will be the first and only full proton therapy system that can fit in an existing LINAC vault.
  • Mevion will officially debut the MEVION S250-FIT Proton Therapy System at ASTROs 64th Annual Meeting in San Antonio, TX.
  • *The MEVION S250-FIT Proton Therapy System, FLASH therapy, online adaptive therapy, and ARC therapy are not yet available for clinical use.

American Shared Hospital Services to Present at the LD Micro Main Event XV

Retrieved on: 
Monday, October 17, 2022
SAN, CA, CFO, Radiosurgery, NYSE, Dream, LD, Index, Pectus carinatum, Malignancy, Company, Proton therapy, CEO, Trigeminal neuralgia, IGRT, AMS, GLOBE, IMRT, Medical imaging

SAN FRANCISCO, CA, Oct. 17, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – American Shared Hospital Services (NYSE American: AMS) (the “Company”), a leading provider of turnkey technology solutions for stereotactic radiosurgery and advanced radiation therapy equipment, facilities, and services, today announced that it will be presenting at the15th Annual Main Event being held on October 25-27, 2022 at the Luxe Sunset Boulevard Hotel, Los Angeles, CA. Ray Stachowiak, CEO, and Craig Tagawa, President and CFO, will present a corporate overview and meet with investors throughout the conference.

Key Points: 
  • Ray Stachowiak, CEO, and Craig Tagawa, President and CFO, will present a corporate overview and meet with investors throughout the conference.
  • The 2022 LD Micro Main Event XV will be held at the Luxe Sunset Boulevard Hotel in Los Angeles from October 25th to the 27th.
  • This three-day, investor conference is expected to feature around 200+ companies, presenting in half-hour increments, as well as private meetings.
  • [email protected]
    LD Micro aims to be the most crucial resource in the micro-cap world.

American Shared Hospital Services Strengthens Management Team with Appointment of Peter Gaccione as Chief Operating Officer

Retrieved on: 
Thursday, September 1, 2022
Well, COO, CA, Security (finance), COVID-19, University, Cancer, NYSE, Trigeminal neuralgia, Management, Leeds Gamma Knife Centre, CMS, Proton therapy, HVS Global Hospitality Services, Radiation, Physician, IMRT, Well known, Century, Neuroscience, Radiosurgery, Hospital, Pain scale, U.S. Securities and Exchange Commission, Union of Sales and Marketing Professionals, GLOBE, Annual general meeting, Leadership, Company, Elekta, Malignancy, IGRT, Risk, AMS, Pectus carinatum, Annual report, Marketing, Cardiology, Industry, Growth, Brachytherapy, Medical imaging

SAN FRANCISCO, CA, Sept. 01, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – American Shared Hospital Services (NYSE American: AMS) (the “Company”), a leading provider of turnkey technology solutions for stereotactic radiosurgery and advanced radiation therapy equipment, facilities, and services, today announced the appointment of Peter Gaccione as Chief Operating Officer (COO), effective September 7th, 2022. Mr. Gaccione assumes the COO position from Craig Tagawa who remains the Company’s President and Chief Financial Officer.

Key Points: 
  • Mr. Gaccione assumes the COO position from Craig Tagawa who remains the Companys President and Chief Financial Officer.
  • Ray Stachowiak, Chief Executive Officer, commented, Were excited to welcome Peter Gaccione as Chief Operating Officer of American Shared Hospital Services.
  • His addition expands and strengthens the management team and the outlook for growth of the Company.
  • About American Shared Hospital Services (NYSE American: AMS)
    American Shared Hospital Services is a leading provider of turnkey technology solutions for stereotactic radiosurgery and advanced radiation therapy equipment, facilities, and services.

Global Radiotherapy Market Report 2022: Rising Cancer Prevalence Worldwide to Drive Growth - ResearchAndMarkets.com

Retrieved on: 
Wednesday, August 17, 2022
Health, Oncology, Hospital, Radiation, Neoplasm, LDR, Growth, Cancer, Incidence, Radiation therapy, IGRT, HDR, IMRT, Awareness, Radiology, CAGR, Particle accelerator, LINAC, Particle therapy, Stereotactic surgery, Prostate, Oncology, Product, USD, Adoption, Medical imaging, Pharmaceutical industry, Breast, Technology

Technological advancements in radiotherapy and the rising incidence of cancer are the major factors driving the growth of this market.

Key Points: 
  • Technological advancements in radiotherapy and the rising incidence of cancer are the major factors driving the growth of this market.
  • Additionally, growing awareness of the benefits of radiotherapy and the increasing use of particle therapy for cancer treatment are other factors driving the growth of this market.
  • The service segment, by type, is expected to register the highest growth rate in the global radiotherapy market during the forecast period 2022-2027.
  • Based on technology, the radiotherapy market has been segmented into external beam radiotherapy and internal beam radiotherapy.